NorthWest Biotherapeutics Inc (NWBO)

[The Danish Dude]

Since NWBO is in a quiet period due to data lock - selfimposed due to tactics or not - we get to know about the outcome of the trial, by looking at the events and incidents surrounding NWBO.

1) We know that NWBO has been working for 14 months to get a publication done in a serious medical journal, which accordingly to statistics takes around 300 days in median time from announcing positive results to publication. We also know that the Covid situation has taken a toll on the process, which has slowed it down. That info can also be found in latest quarterly SEC.

Results: Of the 100 press releases in our sample, 70 (70%) reported positive results, but only 31 (31%) included the magnitude of study findings. Through the end of follow-up, 99 (99%) of press releases had an associated peer-reviewed publication, complete data posting to ClinicalTrials.gov, or both, with a median time to reporting of 300 days (95% CI, 263-348 days). Positive findings were reported more quickly than negative ones (median of 272; 95% CI, 211-318 days vs 407; 95% CI, 298-705 days; log-rank P < .001).

Conclusions and relevance: Even for the most pressing study findings, median publication delays approach 1 year. As publication delays hinder research progress and advancements in clinical care, policies that enable early preprint release or public posting of completed data analysis should be pursued.

2) We know Kristyn Power got hired during the data lock period namely April 1st. and thus left a good manager job to become manager in Toronto. Would she be saying "yes, I would like to wait for TLD and be in the dark of my future till then" or did she get "in the know about her future" before she signed? We all know what she did!

3) Tamara Kondic managing director for Donahoe Consultant and expert in Nasdaq uplisting, got attached as consultant May 1st. and thus joined Bruce Poignant expert on NYSE uplisting.

4) NWBO acquired a lot of patents during the quiet period, ranging from it's DCVax line of vaccines, to Flaskworks technology.

5) Development Completed for Initial Production Capacity of Sawston, UK Facility

6) Application Submitted to MHRA for Certification of Sawston Facility

7) HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility

8) $15 Million Financing

9) Several posters on Ihub have provided DD after DD by digging up information by among other things, talking to essential people and organisations involved somehow in the trial process. One can just mention Lykiris DD from today

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167128751

10) Advent has been hiring immensely with people with GBM, cell and dendritic skills as well as biobanker and cleaners.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167128751

What in the above, did you know about in October 2020?

To me, they are individually bullish bulletpoint, but together an overwhelming indication, that of course nothing has gone wrong regarding the trial.

NWBO is acting with confidence regarding securing patents, making production facilities ready, certification, and much more.

If the above to you equals "not one thing we know now, we didn't know then", then I think we're not on the same page.

They don't mention the trial outcome, because that is "off property" during a quiet period.

But they speak volumes together about it being succesful or not.